About Kedrion Biopharma
Kedrion Biopharma is a Healthcare company based in Fort Lee (United States) founded in 2002. Plasma-derived therapies are provided for rare disease treatment. Kedrion Biopharma has raised $10.84 million across 1 funding round from investors including Simest. The company has 962 employees. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is KEDRION BIOPHARMA INC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Kedrion Biopharma was established in 2002 in Fort Lee, United States, within the biopharmaceutical sector. Plasma-derived therapies are developed and supplied by the company to address rare conditions, including hemolytic disease of the fetus and newborn, immune deficiencies, and hemophilia. Products such as Koate-DVI, an antihemophilic factor, are offered to prevent or treat these disorders. Operations focus on plasma-based solutions distributed across the United States.
- Headquarters Fort Lee, United States
- Employees 962
- SectorsHealthcare
- Phone•••• ••••
- Website kedrion.us
- Social LinkedIn
- Legal Name Kedrion Biopharma Inc.
- Total Equity Funding$10.84M (USD)
in 1 rounds
- Latest Funding Round$10.84M (USD), Series B
Feb 2020
- Investors
- Employee Count962
Funding Insights of Kedrion Biopharma
Kedrion Biopharma has successfully raised a total of $10.84M through 1 strategic funding round. The most recent funding activity was a Series B round of $10.84 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.84M
- Total Rounds 1
- Last Round Series B — $10.84M
- First Round $10.84M
(Feb 2020)
- Investors Count 1
All 1 funding rounds of Kedrion Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $10.84M | Series B | – | Simest | – |
1 investors in total: 1 institutional.
Investors in Kedrion Biopharma
Kedrion Biopharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Simest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manages diversified investment portfolios across various asset classes. | 1991 | simest.it | Rome, Italy |
Investor details for Kedrion Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kedrion Biopharma
21 people are tracked at Kedrion Biopharma (7 in leadership, 14 in team); the tracked headcount is 962.
| Name | Role | Group |
|---|---|---|
Ugo Di Francesco | CEO | Leadership |
Bob Rossilli | President US Operations | Leadership |
Maxime Griffin | Senior Director Of Finance | Leadership |
Joe Gorman | Vice President, US Specialty Sales | Leadership |
Nicholas Leonard | Area Sales Director | Leadership |
Jamie Mattern | National Director, Rare Disease Franchise | Leadership |
Usman Sheikh Aat | Director (accounting, Taxes And Administration) | Leadership |
Charlotte A. Cook Mba | Hospital Regional Business Manager | Team |
Jeanne Lowe | Regional Business Manager | Team |
Uy N. | Sr. Manager, Forecasting And Sales Analytics | Team |
Dominic J. Clementi | Finance Controlling Manager | Team |
Jorge Abdala | Operations Task Force Manager | Team |
Samuel Kastanowski | Task Force Manager | Team |
Eric Cahill | Regional Business Manager | Team |
Melissa Williams | Regional Business Manager | Team |
Carlos Landeros | Rare Disease Specialist | Team |
Daniel Mansell | Corporate Account Manager | Team |
Ryan Miner | Hospital Regional Business Manager | Team |
Julliana Targowski Crt Ae-C | Hospital Regional Business Manager | Team |
Marshal Wallace | Regional Business Manager | Team |
1 more people are available in the full profile.
Complete people profiles for Kedrion Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kedrion Biopharma
2 dated milestones of Kedrion Biopharma across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Kedrion Biopharma is founded.
- Funding First funding round of $10.8M.
Competitors of Kedrion Biopharma
Kedrion Biopharma has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Kedrion Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kedrion Biopharma
The website of Kedrion Biopharma (kedrion.us) receives about 5.6K visits a month.
- Monthly visits5.6K
▼ 32.3% vs previous month
Websites whose visitors overlap most with Kedrion Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| scynexis.com | 100% | 6.5K | #4,483,848 | View details | |
| apcerls.com | 99% | #3,323,878 | View details | ||
| brainstorm-cell.com | 96% | 4.5K | #4,620,847 | View details | |
mt-pharma-america.com | mt-pharma-america.com | 91% | #11,554,805 | – | |
elevartx.com | elevartx.com | 85% | #2,265,362 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Kedrion Biopharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Kedrion Biopharma (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kedrion Biopharma
Complete news archive for Kedrion Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kedrion Biopharma
Kedrion Biopharma was founded in 2002 and raised its 1st funding round 18 years after it was founded.
Kedrion Biopharma is headquartered in Fort Lee, United States. It is registered at Fort Lee, New Jersey, United States.
Kedrion Biopharma is a funded company, having raised a total of $10.84M across 1 funding round to date. The company's 1st funding round was a Series B of $10.84M, raised on Feb 2020.
Kedrion Biopharma has 962 employees.
Kedrion Biopharma was established in 2002 in Fort Lee, United States, within the biopharmaceutical sector. Plasma-derived therapies are developed and supplied by the company to address rare conditions, including hemolytic disease of the fetus and newborn, immune deficiencies, and hemophilia. Products such as Koate-DVI, an antihemophilic factor, are offered to prevent or treat these disorders. Operations focus on plasma-based solutions distributed across the United States.
Kedrion Biopharma's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Kedrion Biopharma has 1 investor. Key investors include Simest.
Kedrion Biopharma operates through Kedrion Biopharma Inc..